These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16888434)

  • 41. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hemophilia A with factor VIII inhibitor].
    Shima M
    Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
    [No Abstract]   [Full Text] [Related]  

  • 43. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
    Economou M; Teli A; Tzantzaroudi A; Tsatra I; Zavitsanakis A; Athanassiou-Metaxa M
    Haemophilia; 2008 Mar; 14(2):390-1. PubMed ID: 18194305
    [No Abstract]   [Full Text] [Related]  

  • 44. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
    Goldsmith JC
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The evidence behind inhibitor treatment with recombinant factor VIIa.
    Ludlam CA
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():13-8. PubMed ID: 12214140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA; Cooper DL; Goldstein B
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII.
    Takedani H
    Haemophilia; 2010 Sep; 16(5):740-6. PubMed ID: 20398072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility of using recombinant factor VIIa in continuous infusion.
    Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
    Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Dose option of haemophilia prophylaxis in children].
    Tang L; Wu RH
    Zhonghua Er Ke Za Zhi; 2012 Jan; 50(1):70-2. PubMed ID: 22456080
    [No Abstract]   [Full Text] [Related]  

  • 51. Family issues in continuous infusion therapy with factor VIII.
    Manco-Johnson MJ
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S21-5. PubMed ID: 8735793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U; Livnat T; Zivelin A; Kenet G
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant.
    Ton-That TT; Doron D; Pollard BS; Bacher J; Pollard HB
    Nat Biotechnol; 2000 Mar; 18(3):289-95. PubMed ID: 10700143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of arthropathy in haemophilia - intensive on-demand treatment, UK perspective.
    Lee CA
    Haemophilia; 2008 Nov; 14 Suppl 6():11-5. PubMed ID: 19134027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.
    Yoshioka A; Nishio K; Shima M
    Haemostasis; 1996; 26 Suppl 1():139-42. PubMed ID: 8904189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacokinetics of coagulation factors.
    Lee M; Morfini M; Negrier C; Chamouard V
    Haemophilia; 2006 Jul; 12 Suppl 3():1-7. PubMed ID: 16683990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activated prothrombin complex concentrate for acquired haemophilia when recombinant factor VIIa fails.
    Hussein Z; Kudva GC; Reimers HJ
    Haemophilia; 2009 May; 15(3):831-2. PubMed ID: 19175418
    [No Abstract]   [Full Text] [Related]  

  • 60. PROPLEX vs. PROPLEX SX: a controlled double blind study of the effectiveness in treating acute hemarthroses in hemophilia A patients with inhibitors to factor VIII.
    Gomperts ED; Fannon RB; Lee ML; Kingdon HS; Kantrowitz JL; Addiego JE; Carney J; Corrigan JJ; Hathaway W; Hilgartner MW
    Thromb Res; 1986 Jun; 42(6):789-96. PubMed ID: 3726800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.